Get 25% discount on our yearly plans! Subscribe now

Key Metrics
Market Cap 1.05B
Total Shares Outstanding 40.49M
Book Value 6.96
PE Ratio -
PS Ratio 7.48
PB Ratio 3.72
Forward PE Ratio 116.28
ROIC -
Return on Aseets -9.19
Return on Equity -12.43
Dividend -
Dividend Yield -
Balancesheet Metrics
Total Assets 318.56M
Total Liability 37.33M
Assets-to-Libability Ratio 8.53
Total Current Assets 293.82M
Total Current Liability 25.88M
Current Ratio 11.36
Quick Ratio 10.5
Debt to Equity Ratio -
Income Statement Metrics
Net Income -48.69M
EPS -0.71
EBITA -45.00M
Gross Profit 4.52M
Gross Profit Margin -19.62%
Operating Margin -21.46%
Net Profit Margin -215.5%
Price Metrics
5 Days MA 25.47
10 Days MA 25.84
20 Days MA 27.68
50 Days MA 30.76
200 Days MA 45.01
52 Weeks High 66.54
52 Weeks low 24.64
All Time High 66.54
RSI 33.52
MACD -
Share Stats
Shares Float 34.75M
Shares Short 2.41M
% Short 0.0676%
% Insider 5.056%
% Institutions 91.192%
News
RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price TargetLast week, you might have seen that RxSight, Inc. (NASDAQ:RXST) released its annual result to the market. The early response was not positive, with shares down 7.0% to US$28.21 in the past week. Revenues came in at US$140m, in line with forecasts and the company reported a statutory loss of US$0.71 ...

RXST | finance.yahoo | about 17 days ago | Neutral
RxSight Full Year 2024 Earnings: EPS Beats ExpectationsRxSight (NASDAQ:RXST) Full Year 2024 Results Key Financial Results Revenue: US$139.9m (up 57% from FY 2023). Net loss: US$27.5m (loss narrowed by 44% from FY 2023). US$0.71 loss per share (improved from US$1.41 loss in FY 2023).NasdaqGM:RXST Earnings and Revenue Growth February 27th 2025 All figu...

RXST | finance.yahoo | about 18 days ago | Neutral
RxSight Inc (RXST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...Revenue: $40.2 million in Q4 2024, up 41% year-over-year. LAL Revenue: $28.5 million in Q4 2024, up 60% year-over-year. LDD Revenue: $10.7 million in Q4 2024. Gross Margin: 71.6% in Q4 2024, up from 61.8% in Q4 2023. SG&A Expenses: $28.2 million in Q4 2024, up 33% year-over-year. R&D Expenses: $9.2 ...

RXST | finance.yahoo | about 19 days ago | Neutral
RxSight, Inc. (RXST) Misses Q4 Earnings EstimatesRxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -70%. ...

RXST | finance.yahoo | about 19 days ago | Neutral
RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 GuidanceRxSight, Inc. ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December ...

RXST | finance.yahoo | about 20 days ago | Neutral
RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025RxSight, Inc. ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024...

RXST | finance.yahoo | about 2 months ago | Neutral
Insider Stock Buying Reaches US$1.83m On RxSightMultiple insiders secured a larger position in RxSight, Inc. (NASDAQ:RXST) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects. Although we don't think shareholders should simply follow insider transactions, we do t...

RXST | finance.yahoo | about 2 months ago | Neutral
RxSight price target lowered to $43 from $66 at Needhamhttps://www.tipranks.com/news/the-fly/irhythm-price-target-raised-to-125-from-112-at-needham Needham lowered the firm’s price target on RxSight (RXST) to $43 from $66 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-anno...

RXST | finance.yahoo | about 2 months ago | Neutral
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 GuidanceRxSight, Inc. ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operati...

RXST | finance.yahoo | about 3 months ago | Neutral
RxSight, Inc. to Present at the J.P. Morgan Healthcare ConferenceRxSight, Inc. ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan He...

RXST | finance.yahoo | about 3 months ago | Neutral

Profile

Rxsight Inc (RXST)

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Exchange: NASDAQ

IPO Date: 7/30/2021

Sector: Healthcare

Industry: Medical Devices

Employees: 498

Address: 100 Columbia, Aliso Viejo, CA, United States, 92656

https://www.rxsight.com

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;12/31/202409/30/202406/30/202403/31/202412/31/202309/30/202306/30/202303/31/202312/31/202209/30/2022Totals
Assets
318.56K310.47K305.50K183.16K182.55K181.85K195.26K202.53K150.16K155.71K3.22M
Current Assets
293.82K286.77K281.22K168.56K168.41K167.95K180.44K187.67K134.56K139.16K2.92M
Cash And Short Term Investments
237.22K237.12K233.28K125.35K127.18K131.88K147.09K153.94K105.80K112.83K2.34M
Net Receivables
30.05K25.37K25.72K21.55K20.28K15.24K13.29K12.67K10.96K9.02K214.95K
Inventory
22.01K21.67K19.44K18.70K17.42K18.92K17.95K18.07K14.84K15.34K248.53K
Other Current Assets
4.54K2.61K2.77K2.96K3.52K1.90K2.11K2.99K2.96K1.97K45.44K
Non Current Assets
24.74K23.70K24.28K14.61K14.14K13.90K14.82K14.87K15.61K16.54K300.69K
Property Plant Equipment
------13.71K9.80K10.14K10.62K124.74K
Long Term Investments
-----------
Non Currrent Assets Other
1.11K9243032261471373487461.53K1.59K18.57K
Liabilities
37.33K33.21K30.29K19.24K22.19K20.37K38.07K57.52K60.26K59.75K1.45M
Current Liabilities
25.88K22.64K19.62K18.33K20.90K18.94K16.57K14.88K17.24K16.37K264.82K
Accounts Payable
4.54K4.58K5.09K5.06K3.86K4.11K4.00K3.72K2.60K4.17K61.09K
Short Long Term Debt
-----------
Other Current Liabilities
17.25K18.06K13.05K10.04K13.19K12.86K10.59K9.18K11.32K10.25K165.44K
Non Current Liabilities
11.45K10.57K10.67K9081.28K1.43K21.51K42.65K43.02K43.38K1.18M
Long Term Debt
-------42.65K-43.38K303.95K
Other Liabilities
------76---3.90K
Stockholder Equity
281.24K277.26K275.21K163.93K160.36K161.48K157.19K145.01K89.90K95.96K1.42M
Preferred Stock Equity
-----------
Liabilities And Stockholders Equity
318.56K310.47K305.50K183.16K182.55K181.85K195.26K202.53K150.16K155.71K3.12M
Common Equity
-------342828206
Retained Earnings
--------559.24K-546.03K-530.42K-4.04M
Totals1.63M1.59M1.55M935.78K938.00K932.82K1.03M562.20K275.05K361.35K431.61K490.54K586.88K654.82K-221.14K889.02K718.91K--13.35M
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;12/31/202412/31/202312/31/202212/31/202112/31/202012/31/2019Totals
Assets
318.56K182.55K150.16K192.72K100.68K110.43K1.06M
Current Assets
293.82K168.41K134.56K176.29K81.50K90.20K944.78K
Cash And Short Term Investments
237.22K127.18K105.80K159.33K68.97K80.67K779.18K
Net Receivables
30.05K20.28K10.96K4.86K2.87K78969.80K
Inventory
22.01K17.42K14.84K8.03K8.29K7.22K77.80K
Other Current Assets
4.54K3.52K2.96K8.14K1.37K1.52K22.06K
Non Current Assets
24.74K14.14K15.61K16.43K19.18K20.23K110.33K
Property Plant Equipment
--10.14K11.22K18.61K19.25K59.21K
Long Term Investments
-------
Non Currrent Assets Other
1.11K1477671141109833.23K
Liabilities
37.33K22.19K60.26K54.48K398.21K415.04K987.50K
Current Liabilities
25.88K20.90K17.24K11.08K11.60K8.46K95.15K
Accounts Payable
4.54K3.86K2.60K1.69K1.13K2.20K16.02K
Short Long Term Debt
-------
Other Current Liabilities
17.25K13.19K9.35K5.71K9.19K4.89K59.59K
Non Current Liabilities
11.45K1.28K43.02K43.40K386.61K406.59K892.35K
Long Term Debt
---43.40K--43.40K
Other Liabilities
----136.89K189.68K326.57K
Stockholder Equity
281.24K160.36K89.90K138.24K-297.53K-304.61K67.60K
Preferred Stock Equity
-------
Liabilities And Stockholders Equity
318.56K182.55K150.16K192.72K100.68K110.43K1.06M
Common Equity
--282780.78K56.42K137.26K
Retained Earnings
---546.03K-479.28K---1.03M
Totals1.63M938.00K272.32K588.61K1.13M1.22M5.78M
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;06/30/202203/31/202212/31/202109/30/202106/30/202103/31/202112/31/202009/30/202006/30/202003/31/2020Totals
Revenue
11.36K8.94K8.43K5.79K4.90K3.48K4.91K4.17K2.71K2.89K57.57K
Cost Of Revenue
6.57K5.18K5.56K4.45K5.71K2.37K3.53K3.45K3.18K2.81K42.80K
Gross Profit
4.79K3.76K2.87K1.34K-8121.12K1.38K720-4747814.77K
Operating Expenses
20.58K20.34K17.53K14.45K13.06K12.25K13.21K9.63K11.51K9.47K142.05K
Selling General Administrative
14.39K13.62K11.62K9.08K6.50K5.61K4.40K3.83K3.25K-72.29K
Research Development
6.19K6.72K5.92K5.38K6.56K6.64K5.27K5.80K5.08K5.78K59.34K
Other Operating Expenses
27.15K25.52K23.09K18.90K-14.62K-13.08K-12.29K134.64K
Operating Income
-15.79K-16.58K-14.66K-13.11K-13.88K-11.13K-8.29K-8.91K-8.81K-9.40K-120.56K
Net Interest Income
-940-1.01K-1.07K-1.07K-811-681-47760143--5.86K
Interest Income
19646101115172163147-526
Interest Expense
1.14K1.06K1.08K1.08K8266984983456.39K
Other Income Expense Net
-940-1.01K-1.07K4351.21K4.34K35.07K39.58K-4.18K-7.10K66.33K
Income Before Tax
-16.73K-17.59K-15.73K-12.68K-13.47K-6.80K26.30K30.67K-12.84K-16.50K-55.37K
Tax Provision
-42-4374840-64
NetIncome
-16.73K-17.60K-15.73K-12.67K-13.48K-6.80K26.30K30.66K-12.88K-16.50K-55.44K
NetIncome Applicable To Common Shares
-16.73K-17.60K-15.73K-12.67K-13.48K-6.80K-5.90K-16.98K-20.75K-114.84K
Ebit
-15.60K-16.53K-14.65K-11.60K-12.65K-6.10K-30.68K-8.81K-16.49K-71.75K
Basic EPS
--0.64-0.58-0.68-0.51--1.7----4.11
Totals8.90K-2.73K-2.56K-2.90K-29.78K12.83K112.13K169.38K-38.90K-53.42K172.94K
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;12/31/202112/31/202012/31/2019Totals
Revenue
22.59K14.68K2.24K39.51K
Cost Of Revenue
18.08K12.97K4.06K35.11K
Gross Profit
4.52K1.71K-1.82K4.40K
Operating Expenses
57.30K37.11K44.77K139.19K
Selling General Administrative
32.80K15.18K15.20K63.18K
Research Development
24.50K21.93K29.57K76.00K
Other Operating Expenses
75.38K50.08K48.83K174.29K
Operating Income
-52.79K-35.41K-46.07K-134.27K
Net Interest Income
-3.63K332.28K-1.31K
Interest Income
545432.31K2.90K
Interest Expense
3.68K510264.22K
Other Income Expense Net
4.11K63.04K172.31K239.47K
Income Before Tax
-48.68K27.63K126.24K105.20K
Tax Provision
8572489
NetIncome
-48.69K27.57K126.22K105.11K
NetIncome Applicable To Common Shares
-48.69K3.37K26.13K-19.20K
Ebit
-45.00K28.14K126.27K109.41K
Basic EPS
-1.77-1.7--3.4699999999999998
Totals-4.45K269.15K678.60K943.30K
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;12/31/202409/30/202406/30/202403/31/202412/31/202309/30/202306/30/202303/31/202312/31/202209/30/2022Totals
Cash From Operating Activities
-4.26K650-4.11K-9.31K-9.89K-7.98K-7.55K-17.76K-13.85K-15.19K-198.97K
Net Income
-5.94K-6.34K-6.08K-9.10K-9.18K-12.41K-13.80K-13.21K-15.61K-16.82K-163.93K
Depreciation
5231.14K8201.14K1.08K1.13K1.03K99996198019.89K
Extraordinary Items
-----------
Change Receivables
--------1.71K-1.94K-2.14K-7.81K
Change To Inventory
-408-2.40K-799-1.39K1.35K-977117-3.24K203-4.05K-18.71K
Change To Liabilities
--------2.33K7303.35K1.61K
Change To Net Income
-------3.31K3.26K3.22K-7.94K
ChangeToOperatingActivities
-------2.81K-2.88K4.98K
Cash flows From Investing Activities
--------48.37K10.40K560-60.22K
Capital Expenditures
-847-1.10K-1.52K-1.97K-1.59K-653-1.82K-747-362-580-17.13K
Other Cashflows From Investing Activities
-----------
Cash From Financing Activities
2.98K878111.55K7.99K5.15K-8.23K89165.31K6.31K-455355.42K
Net Borrowings
--------20.04K-1-2-5.26K
Sale Purchase Of Stock
-2.13K1--2-1.08K--337-1.48K-150124
Dividends Paid
-----1.08K-337--1.42K
Other Cashflows From Financing Activities
-889-376-2.13K-6104017.64K8681.49K-578142.89K
Cash And Cash Equivalents Changes
--------8242.86K-15.08K-13.39K
Totals-7.95K-4.15K99.49K-14.77K-13.68K-29.09K-3.49K-34.95K-7.03K-44.05K-16.01K-17.13K-52.77K133.38K15.88K10.07K43.49K-7.51K-15.76K-98532.99K
&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;12/31/202412/31/202312/31/202212/31/202112/31/202012/31/2019Totals
Cash From Operating Activities
-16.95K-41.59K-58.85K-44.71K-35.20K-40.62K-237.92K
Net Income
-27.45K-48.61K-66.76K-48.69K27.57K126.22K-37.71K
Depreciation
3.62K4.24K4.02K3.99K4.01K3.93K23.82K
Extraordinary Items
-------
Change Receivables
---6.09K-2.00K---8.09K
Change To Inventory
-4.99K-2.75K-7.55K-2.11K-1.31K-5.47K-24.19K
Change To Liabilities
--5.45K4.24K-9541.13K9.87K
Change To Net Income
--12.15K7.22K-59.03K-166.80K-206.45K
ChangeToOperatingActivities
--5.60K874-3.51K1.16K4.12K
Cash flows From Investing Activities
--39.95K-81.91K15.59K-5.87K-32.24K
Capital Expenditures
-5.44K-4.81K-2.39K-1.94K-2.54K-4.09K-21.21K
Other Cashflows From Investing Activities
-------
Cash From Financing Activities
123.32K61.52K6.33K137.34K25.24K1.33K355.08K
Net Borrowings
---14514.87K24.86K-18539.40K
Sale Purchase Of Stock
--1.42K-643121.93K--119.86K
Dividends Paid
--643---643
Other Cashflows From Financing Activities
--4.28K-1.38K1.23K3791.51K-2.53K
Cash And Cash Equivalents Changes
---12.57K10.73K---1.84K
Totals72.11K-37.70K-82.23K121.07K-4.89K-87.75K-19.39K